This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.

1. CONCEPTUALIZATION ON GLOBAL HEALTH-TECH INDUSTRY
ANIRBAN BHATTACHARJEE

2. TOPICS OF DISCUSSION
1
2
3
4
5
6
The Healthcare & Life Sciences Industry
2020
Analysis of attractiveness of each sub segments
The Post Covid-19 Disruption
Technologies & start-ups disrupting the status quo
Special focus on medical device industry: Global vs Indian
A concept note on syringe counterfeiting

3. Niche
Specialist
The New Healthcare Model
Important Players (*Proposed by KPMG)
Active
Portfolio
Companies
1. Healthcare’s reliance on digital
technology has risen. Healthcare 4.0:
Patient wearables, data analytics,
patient monitoring systems
2. Growth of quantum tech, AI in drug
development as well in the technology
which acts the medium of the
healthcare service
3. Covid-19 has increased the growth of
companies involved in support systems
eg IT, ITeS, Supply chain transformation
eg temperature controlled chains,
blockchain
4. Shift to outcome based care from value
based
Key Takeways
Virtual
Value chain
orchestrator
Challenges
Siloed data | Privacy of data | Cost
pressures & price ceilings by regulatory
bodies | Heterogeneous regulations|
Hyper competition in generics
Late stage
development
companies
Digital Tech/data
based company
Early stage
clinical discovery

4. KEY NUMBERS FROM PRIMARY
ANALYSIS
27 %
17.8
mn $
~ 2%
5.2
mn $
Biotech increase in total
funding over the last 5 years.
Maximum over other categories in
healthcare
Largest funding/deal:
Drug Discovery & drug
development 2nd fastest growing
segment and still has
Average Medical device funding
growth (*last 5 years). Remained
constant. Funding/deal has decreased.
Highest funding in Imaging, surgical &
therapeutic devices
Indias Medtech funding/deal (2020)
In india funding in line with global
average. Highest funding for AI
enabled healthcare services
Changes
observed?
1
2
3
4
• Biotech/Pharmac
eutics related
companies fastest
growing
• Patient
Monitoring
systems
generated more
funding than
expected, owning
to telehealth
demand
• Global Giants
Abbott, GE,
Phillips opened
incubation
programs leading
to medtech
funding
comparable to
global average
• Among
CBInsights top
150 startups
clinical
intelligence
biggest
technology while
healthcare
software &
services biggest

5. Virtual consultations by healthcare professionals will
become the mainstream care delivery model post-
pandemic. , 73% of the deals in 2020 globally have been
seed/angel or early-stage deals indicating that this
industry has a lot of opportunity for investors
Informatics and artificial intelligence (AI)
solutions addressing workflow automation and
operational analytics will witness 100% growth in
2020. eg. GE Healthcare‘s industry-first, FDA-
cleared Critical Care Suite AI tool. Teleradiology
& new patient delivery models for critical care to
drive growth
Rise of Covid-19 & Other Infectious Diseases:
Although diagnosis & treatment of lifestyle
diseases were the primary area of focus the 5bn
$ estimated infectious disease market became
the centre of attention. Walgreens & CVS trying
alternate models from traditional in-vitro testing
Segmentation of Market: The healthcare
industry includes various sub segments: The
major ones: pharma/life sciences, medical
devices, care delivery services,
insurance/payers. Across the service chain
segmented into Prevention, diagnosis,
treatment care
The rise of biotech: Both in terms of deal size
& funding. Med/biotech hits its highest
funding quarter since 20I8 Med/biotech
funding reached $6.2 billion in Q1 2020, the
highest quarter ever since Q3 2018
Funding Trends: 2020 fundings remained as
per the projected standards at 48 bn $
(including private equity deals). Growth driven
by the further rise of digital health companies
& biotech drug development.
The Healthcare Industry 2020: Key Insights

6. MAJOR DISRUPTOR:
TELEMEDICINE
The Covid disruption reduced funding of traditional healthcare services.
Need for faster care delivery models. Live monitoring, in home testing
were trends
81 bn $
21 %
Representatio
n in top 150
digital
startups list:
Estimated
Market
Potential
62 %
Teleconsultati
on &
Specialized
Tele Services
in India as a %
of total Tele-
heath Cos
A C C E L E R A T E D
D I G I T A L
P E N E T R A T I O N
L E S S W A I T I N G
T I M E , P R I M A R Y
H E A L T H C A R E
C O S T
D A T A
S E C U R I T Y |
R E G U L A T I O
N S
P E R C E P T I O N
A B O U T
Q U A L I T Y
I N F R A S T R U C T U R E
&
I N T E R O P E R A B I L I T Y

7. 1. Industry Average
Importance of Digital Tech
• AI, ML and Cloud
forming the backbone of
healthcare analytics
• Lifesciences 4.0 with a
patient centric
personalized medicine
• Based on number of deals
Data Management, wellness,
genomics top 3
• In medical device category:
max investment in
diagnostics
• Based on number of startups
since 2010 wellness,
genomics top category
• Microsoft ScaleUp & Microsoft
AI Factory: 35 investments
• Venture arm M12: Late stage
funder
• Top invested categories: Data
Management & Analytics and
Genomics companies
• Google Launchpad
Accelerator: 17 digital
health companies
• The top categories of
investment Genomics (18
deals), Clinical Research
(15), and Insurance &
Benefits (12)
• 31 investment in china & 18
in US
• 84 % investment + 16 %
from Accelerator program
• the two top investment
categories by deal volume
are Clinical Research and
Administrative Tools
WHERE DO BIG TECH GIANTS
INVEST?
Startups Invested in

8. Next-generation sequencing
(NGS):
3D-printing
Artificial intelligence (AI)
• Point-of-care (POC) diagnostics
Healthcare -
Life Sciences
Sector
Immunotherapy
Quantum Computing: From 15 years and costing $3
billion to 45 genomes/day at 1000$ for NGS.
2 lakh Amputations/year in US alone. 3d organs &
prosthetics can reduce cost from 50k $ to 100-500
$
Oncology is the biggest end use of all drug
development. Immunotherapy in the form of
Cart T tech, RNA therapy
Healthcare Companies using AI received higher
funding (1.8 mn $) vis a vis non adopters. Application
of AI for new drug development deals increased 5x in
last 5 years
Analysts expect the market for POC diagnostics will
total nearly $3 billion in 2021, up from $2.13 billion in
2015. Shift from FFS to Value Based Care to drive
growth
01
02
03
05
04
TOP TRENDS IDENTIFIED Technology Deep-Dive

9. Virtual reality (VR)
SML: Social Media
Listening
Convenient care
Telehealth
Healthcare -
Life Sciences
Sector
Biosensors and trackers
52 percent of consumers actively search online
for health. SML can access patient care data,
Quality of Life measure improvements in care.
CCS Insights expects 411 million wearable
devices to be sold in 2020.
77 percent of respondents of US Consumer
Survey 2018 choose retail clinics for their
convenience, 72 percent for speed of securing
an appointment, and 60 percent for after-hours
care
Even before Covid patent fillings among US
assisted care higher for Telehealth
equipments. Well being & care delivery apps
received highest funding 3.6 bn $ in 2019
06
07
08
10
09
TOP TRENDS IDENTIFIED Technology Deep-Dive
Research articles in Pubmed database have
increased over the last decade from 204 in 2004
to 720 in 2014 to 2567 in 2018 for VR. Proof of
concept: Facebook’s Oculus Rif

10. • US$2 billion deal to
acquire US home
dialysis equipment
maker NxStage
Medical Inc.
• 3,690 dialysis centers
making them a
global leader in both
manufacturing &
clinic operations.
• Focus on home
treatment Market
through the deal
• Partnered with
Fitbit & IBM
Watson
• To integrate
tracking for
patients living
with diabetes
• Augment data
for their
diabetes
management
app, Sugarwise
It is when incumbents perform
the NPD process by outsourcing
or patent sharing, acquisition of
a small niche player.
Advantages: Cost Effective,
Increases GTM time, benefit of
synergy
What is co-
invention?
• Strategic alliance
with IBM Watson
Health
• Focus on
population health
management and
value based
healthcare solutions
for hospitals
• To improve clinical
laboratory service
operations, and is
expected to benefit
more than
92 million patients
A look at corporate VC funding over the last
decade shows that it has been steady & constant.
Reason? Most incumbents invest in technologies
with long term benefits for more effective portfolio
optimization
Key Takeaway: Mapping key focus area of
investments by incumbents helped to shortlist
startups
THE TREND OF CO-
INVENTION
Fresenius Medical Siemens Medtronic

11. LIST OF SELECT STARTUPS
DISRUPTING THE STATUS QUO
Startups disrupting Labcorp’s traditional
health services model across the supply
chain

12. MEDICAL DEVICES: SNAPSHOT
Drug delivery and patient monitoring will personalize and
minimize invasiveness of drug delivery, through devices like
biostamps and smart inhalers. Novartis has partnered with
Qualcomm Life to develop an internet-connected inhaler
Assistive care and therapy services – like the biohybrid kidney –
will minimize the need for certain services (e.g. dialysis).
University of California have developed a first prototype of an
artificial implantable kidney the size of a coffee cup
Ingenious diagnosis and imaging will utilize DNA, nanobots and
Artificial Intelligence (AI) to speed up diagnosis, imaging
Innovative surgical interventions like autonomous surgical
robots and intelligent balloon catheters. Stryker launched FDA
approved robotic-arm assisted total knee arthroplasty

13. MEDICAL DEVICES: SNAPSHOT
care
23%
Diagnosis
19%
Prevention
8%
Treatment
50%
% breakup of stage of application
of Medical devices
care
Diagnosis
Prevention
Treatment
M A P P I N G S T A G E O F A P P L I C A T I O N O F S T A R T U P S I N V E S T E D B Y G E V E N T U R E , J & J
I N N O V A T I O N S H O W S M E D I C A L D E V I C E S F O R T R E A T M E N T A S P R I M A R Y A R E A O F
I N V E S T M E N T
N O N I M A G I N G D I A G N O S T I C S E A R N E D H I G H E R M A R G I N S T H E R E F O R E L E S S F O C U S O N
T H E M B Y I N C U M B E N T ’ S V C A R M S . R A D I O C A R D I O L O G Y , O N C O L O G Y M A I N A R E A O F
A P P L I C A T I O N
A L L I N C U M B E N T S I N V E S T I N A P R I M A R Y A R E A F O R S Y N E R G Y B E S I D E S M U L T I P L E
S E C O N D A R Y I N V E S T M E N T S . E G . J & J F O R I M A G I N G , A B B O T T : T D C A R D I O V A S C U L A R ,
B & D , M E D T R O N I C : T D , G E : R E S E A R C H E Q U I P M E N T S
Key Observations
Focus on patient centric modelling
KPI= Clinical + PROM (patient
related outcome measures)
India in growth phase while China
and USA in the saturation phase
Shift from Channel partner to a
solution provider
Top Indian Startups
• CBInsighst Top 150
• Ai enabled
• 16 mn $ funding, 6458
Crunchbase rank

14. SYRINGE
COUNTERFEITING
Pharma
Company
Initiatives
Brand
recognitio
n
Regulator
y Control
Consumer
Education
Tech
Based
Tracking
Retailer
Recognitio
n
How to
stop
counterfeiti
ng?
U S $ 1 6 3 B I L L I O N T O $ 2 1 7 B I L L I O N I N L O S T S A L E S | 1 0 % O F A L L M E D I C A L
P R O D U C T S C O U N T E R F E I T S | W H O E S T I M A T E S 5 0 % O N L I N E M E D I C A L
P R O D U C T S A S F A K E
B ) D E V I C E C O M P O N E N T S : C A R D I O V A S C U L A R
A N D O R T H O P E D I C P R O D U C T L I N E S
M A R K E T P O T E N T I A L : L O S S I N C O S T S 1 – 2 % O F R E V E N U E S & L O S S I N
R E V E N U E S I S 0 . 7 – 1 . 4 % O F R E V E N U E S . A V G T I M E T O R E U S E A F T E R
C O U N T E R F E I T R E P O R T I N G : 8 8 M O N T H S
T R A D I T I O N A L
C L A S S I F I C A T I O N O F A N T I -
C O U N T E R F E I T I N G T E C H
C O V E R T : 6 0 % O F
A L L
T E C H N O L O G I E S
Types Of
Counterfeit
products
A ) F I N I S H E D P R O D U C T S : B L O O D G L U C O S E
M O N I T O R I N G S Y S T E M S , S U R G I C A L S U T U R E S ,
C A T H E T E R S A N D H E A R T V A L V E S .
O V E R T : 1 0 %
F O R E N S I C
A N A L Y S I S : 3 0 %

15. NEW AGE TECHNOLOGIES
Nano-
Tech
Nano barcodes
Holography
Nanocompos
ite tags
Laser surface
authenticatio
n
Block-
chain
based
Supporting Tech
unique
cryptographic
identifiers
smart tags
IoT + Cloud
Quantum
Dots
Implant SER
technology
Encoding
Technology:
Quantum Codes
Master
batch
variety of polymers
polyamides
Acetal (POM)
PP, PE, PC
Challenges
Economic Barriers: Taggants costlier +
Cost to incorporate these packaging
techs range from 15-150 INR/tag
Technological challenge: Technology
to read these covert tech not accessible
SC TRANSFORMATIONS
Serialization L1 L2 L3 L4 L5
Device
Level
Packaging Site
Enterprise
Wide
Network
Serializatio
n + IoT +
Cloud
Benefits

16. Quantum Computing
• Cryptoseal: Funding $ 330 M, 6
Rounds, 13 investors
• Aquired by: Cloudfare
• Investors Y-Combinator
Product Technologies Supply Chain
transformations
PROOF OF CONCEPTS
Nano Tech Block chain
SMART SYRINGES
• Bit Encryption Assurance level 6+
• Deals with Merck, Pfizer worth 4bn $
• Imprinted on both glass & plastic
vials
• Patented Technology
Serialization
• L1-L5 Serialization end to
end
• Integrated with
appointment-booking
service DocSuggest + in-
home physician visits: Portea
Medical Group
• Packaged 300 mn codes
• Compliance with EU FMD,
DSCSA, DGFT, Saudi FDA and
Russia
Codes & Tag
generators
Crunch-
base Rank:
285241
Funding:
5.5 mn $
Familiar Handling | Tamper proof
| Retractable | Prefilled

17. THANK YOU